Articles
<![CDATA[IDENTIFICATION OF INFLUENZA VIRUSES IN HUMAN AND POULTRY IN THE AREA OF LARANGAN WET MARKET SIDOARJO-EAST JAVA, INDONESIA ]]>
<![CDATA[Frederika, Edith]]>;
<![CDATA[Mareta, Aldise]]>;
<![CDATA[Poetranto, Djoko]]>;
<![CDATA[Wulandari, Laksmi]]>;
<![CDATA[Setyoningrum, Retno Asih]]>;
<![CDATA[Setyowati, Lucia Landia]]>;
<![CDATA[Yudhawati, Resti]]>;
<![CDATA[Soegiarto, Gatot]]>;
<![CDATA[Yamaoka, Masaoki]]>
<![CDATA[ Indonesian Journal of Tropical and Infectious Disease Vol 4, No 4 (2013) ]]>
Publisher : <![CDATA[Institute of Topical Disease ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (2006.144 KB)
<![CDATA[Background: Influenza is a viral infection that attacks the respiratory system (nose, throat, and lungs) that commonly known as âfluâ. There are 3 types of influenza viruses, such as type A, type B, and type C. Influenza virus type A is the type of virus that can infect both human and animals, virus type B are normally found only in human, and Influenza virus type C can cause mild illness in human and not causing any epidemics or pandemics. Among these 3 types of influenza viruses, only influenza A viruses infect birds, particularly wild bird that are the natural host for all subtypes of influenza A virus. Generally, those wild birds do not get sick when they are infected with influenza virus, unlike chickens or ducks which may die from avian influenza. Aim: In this study, we are identifying the influenza viruses among poultry in Larangan wet market. Method: Around 500 kinds of poultry were examined from cloacal swab. Result: Those samples were restrained with symptoms of suspected H5. The people who worked as the poultry-traders intact with the animal everyday were also examined, by taking nasopharyngeal swab and blood serum. Conclusion: Identification of influenza viruses was obtained to define the type and subtype of influenza virus by PCR.]]>
<![CDATA[PENINGKATAN EKSPRESI LAMININ NAMUN TIDAK VE-CADHERIN PADA SAWAR DARAH OTAK SETELAH INFEKSI Mycobacterium tuberculosis INTRAPULMONALIS ]]>
<![CDATA[Widayati, Aris]]>;
<![CDATA[Wulandari, Laksmi]]>;
<![CDATA[Riawan, Wibi]]>
<![CDATA[ Majalah Kesehatan FKUB Vol 5, No 3 (2018): Majalah Kesehatan ]]>
Publisher : <![CDATA[Faculty of Medicine Universitas Brawijaya ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (658.512 KB)
|
DOI: 10.21776/ub.majalahkesehatan.005.03.3
<![CDATA[Tuberkulosis merupakan masalah kesehatan utama di dunia. Pada tahun 2016, WHO menemukan angka kejadian TB kurang lebih 10,4 juta, dan untuk Indonesia dilaporkan sebesar 156.723 kasus. Meskipun penyebaran Mycobacterium tuberculosis di susunan saraf pusat tercatat hanya 1%, namun memiliki tingkat kecacatan dan kematian yang tinggi, sehingga menuntut adanya tatalaksana yang efektif untuk mengatasinya. VE-chaderin dan laminin merupakan protein adhesin yang berfungsi mengendalikan permeabilitas pembuluh darah dan mempertahankan integritas blood brain barrier, sehingga kedua protein adhesin tersebut dapat menjadi salah satu target terapi tuberkulosis otak. Penelitian ini bertujuan untuk mengetahui efek paparan M. tuberculosis secara inhalasi terhadap ekspresi laminin dan VE-chaderin pada sel endotel blood brain barrier. Penelitian ini menggunakan mencit Balb/c (Mus musculus) yang diinfeksi oleh M.tuberculosis strain H37Rv secara inhalasi. Jaringan otak diperiksa menggunakan metode imunohistokimia dengan antibodi mt-38, antibodi VE-chaderin dan laminin. Hasil penelitian menunjukkan adanya invasi M. tuberculosis pada mikroglia jaringan otak mencit, diiketahui juga adanya peningkatan ekspresi laminin, sedangkan VE-chaderin tidak menunjukkan adanya perubahan. Proses masuknya M. tuberculosis ke otak diduga terjadi melalui proses diapedesis atau melalui peningkatan ekspresi laminin tanpa perubahan pada VE-chaderin dan reseptor laminin diduga sebagai tempat berikatan yang memungkinkan bakteri tersebut masuk ke jaringan otak. ]]>
<![CDATA[Viral Profile and Clinical Characteristic in Acute Asthma Exacerbation Patients ]]>
<![CDATA[Resti Yudhawati]]>;
<![CDATA[Erwin Winaya]]>;
<![CDATA[Laksmi Wulandari]]>;
<![CDATA[Aldise M Nastri]]>;
<![CDATA[Retno A Setyoningrum]]>;
<![CDATA[Kazufumi Shimizu]]>
<![CDATA[ Indian Journal of Forensic Medicine & Toxicology Vol. 15 No. 2 (2021): Indian Journal of Forensic Medicine & Toxicology ]]>
Publisher : <![CDATA[Institute of Medico-legal Publications Pvt Ltd ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.37506/ijfmt.v15i2.14872
<![CDATA[Background: Asthma is a heterogeneous disease characterized by chronic airway inflammation. Thevirus infection in respiratory tract will activate greater pro-inflammatory cytokines in asthma patients.The enhancement of pro-inflammatory cytokines induces various clinical symptoms. This study aims toinvestigate the respiratory virus and clinical characteristics among patients with acute asthma exacerbation.Methods: In this study, subjects were divided into 3 groups based on acute asthma exacerbation triggers.The first group triggered by virus infection; the second group triggered by non-virus infection with ILI; andthe third group without any infection. Nasopharynx or throat swabs were collected to detect any respiratoryvirus. Virus was detected by Multiplex PCR (xTAG Respiratory Viral Panel Fast V2/ LUMINEX)Results: According to PCR examination, the prevalence of virus infection was 46.2%. Only two types ofviruses identified, which were Influenza A virus and Rhinovirus. All patients in the second groups showeda symptom of cough with purulent sputum, while no patients from the other two groups showed similarsymptoms. PEFR and % PEFR prediction of patients with Influenza A virus infection were higher than inRhinovirus infected-patients (210 L/min and 48.6% vs 195 L/min and 45%).Conclusion: Acute asthma exacerbation is one of the most reasons patients came to emergency ward. Themajority of acute asthma exacerbation was caused by infection, and most of it was viral infection. Clinicalsign differs according to the trigger, therefore the use of antibiotics should be avoided, unless there are signsand symptoms of bacterial infections]]>
<![CDATA[Comparison of the Efficacy of Generation 1 and 2 Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Patients with EGFR Positive Mutations ]]>
<![CDATA[Suwandi]]>;
<![CDATA[Laksmi Wulandari]]>;
<![CDATA[Gatot Soegiarto]]>
<![CDATA[ Indian Journal of Forensic Medicine & Toxicology Vol. 15 No. 3 (2021): Indian Journal of Forensic Medicine & Toxicology ]]>
Publisher : <![CDATA[Institute of Medico-legal Publications Pvt Ltd ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.37506/ijfmt.v15i3.15970
<![CDATA[Background: The use of TKI generation 1 (Gefitinib, Erlotinib) and Generation 2 (Afatinib) has become thestandard therapy for JPIC pulmonary adenocarcinoma type with positive EGFR gene mutations.Objective: to analyze the comparison of the efficacy of TKI generation 1 and 2 in NSCLC patients withpositive EGFR mutations.Methods: The design of this study used a retrospective in which the participants who received EGFR therapyfor TKI generations 1 and 2 were compared its efficacy. Data collected included health-related quality of life(HRQOL), body weight, performance status (PS), Response Evaluation Criteria in Solid Tumors (RECIST)of thoracic CT, Common Terminology Criteria for Adverse Events (CTCAE), progression free survival(PFS) and overall survival (OS). The statistical analysis used was the independent t test, Mann Whitney test,or Kruskal Wallis test with p <0.05.Results: Most of the participants’ quality of life scores did not change before and after therapy, where theEQ5D value was 67.5% (group 1 = 60.6%; Group 2 = 94.1%; p = 0.806). The participant’s weight decreasedby 49.5% (group 1 = 45.9%; group 2 = 60.0%; p = 0.658) and the participant’s PS was stable (group 1 =29.4%; group 2 = 50.0%; p = 0.014). The RECIST value of the participant was progressive disease 51.0% (p= 0.338). CTCAE differed in stomatitis (p <0.001), paronychia (p <0.001), and diarrhea (p <0.001). Therewas no significant difference between the first and second groups in the PFS (p = 0.197) and OS (p = 0.740)values.Conclusion: EGFR therapy for TKI generations 1 and 2 have almost the same efficacy, in which there is nosignificant difference in the quality of life of the participants.]]>
<![CDATA[ANALISIS PENGARUH GOOD CORPORATE GOVERNANCE DAN MANAJEMEN LABA TERHADAP CORPORATE ENVIRONMENTAL DISCLOSUREPADA PERUSAHAAN PERTAMBANGAN YANG TERDAFTAR DI BURSA EFEK INDONESIA DAN PROPER PERIODE 2012 –2014 ]]>
<![CDATA[Wulandari Laksmi]]>
<![CDATA[ Jurnal Ilmiah Akuntansi & Bisnis Vol 1 No 1 (2016) ]]>
Publisher : <![CDATA[Universitas Pendidikan Nasional ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.38043/jiab.v1i1.20
<![CDATA[The trend toward environmental awareness has brought a change in attitude of orientation towards profit orientation of the company environment. Management as agents can not avoid the reality of the impact of the company’s activities were not only generate profits and raise share prices, but also have environmental impacts such as damage to ecosystems, pollution, wastewater and waste all of which are the responsibility of companies that deal with environmental aspects.This study aimed to examine the effect of earnings management and good corporate governance of the Corporate Environmental Disclosure (CED). Earnings management is measured by discretionary accruals.Population of this research are 44 mining companies listed on the Stock Exchange in 2012-2014. The data used in this study comes from the annual report and sustainability report mining companies listed on the Stock Exchange and Corporate Performance Rating Program (PROPER) in 2012 for a total of 5 companies. The sample is obtained by using purposive sampling method. Hypothesis testing method used is multiple regression analysis. The results showed that the number of audit committee meetings significantly influence the Corporate Environmental Disclosure. Meanwhile, earnings management, the proportion of independent board does not significantly influence the Corporate Environmental Disclosure. Simultaneously good corporate governance and earnings management significantly influence the Corporate Environmental Disclosure.]]>
<![CDATA[LYMPHOCYTE-T TYPE TH1 AND TH2 ACTIVITY DIFFERENCE OF LUNG TISSUE ON Heligmosomoides polygyrus NEMATODE AND Mycobacterium tuberculosis SEQUENTIAL CO-INFECTION ]]>
<![CDATA[Laksmi Wulandari]]>;
<![CDATA[Muhammad Amin]]>;
<![CDATA[Soedarto Soedarto]]>;
<![CDATA[Gatot Soegiarto]]>
<![CDATA[ Folia Medica Indonesiana Vol. 53 No. 2 (2017): JUNE 2017 ]]>
Publisher : <![CDATA[Faculty of Medicine, Universitas Airlangga ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (371.852 KB)
|
DOI: 10.20473/fmi.v53i2.6356
<![CDATA[Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis that are often associated with uneffectiveness of the BCG vaccine and the high worm infection. The objective of this study was to determine the differences in the activity of Limfosit T type Th1 (IFN-g) and Th2 (IL-4) in lung tissue on Heligmosomoides polygyrus nematode and Mycobacterium tuberculosis sequential co-infection. This research using 49 mice were divide into 7 groups treated with infection by Mycobacterium tuberculose inhaled and Heligmosomoides polygyrus orally within 8 and 16 weeks. The levels of IFN-g in peripheral blood serum (89.929 + 3.533 pg/mL) resembles the pattern of the percentage of lymphocytes T CD4+ Th1 in lung tissue (3.246 + 0.519%) and peripheral blood (4.950 + 0.237%), while the levels IL-4 in the peripheral blood serum (20.782 + 4.043%) resembles the pattern of the percentage of lymphocytes T CD4+ Th2 in intestinal tissue (1.048 + 0.359%) and peripheral blood (1.196 + 0.557%). In conclusion, there is difference in the activity of lymphocytes T type Th1 and Th2 but it does not affect the immune response to Mycobacterium tuberculosis infection.]]>
<![CDATA[COMPARISON OF CHEMOTHERAPY RESPONSE AND ADVERSE EFFECTS OF DOUBLE-PLATINUM PLUS EGFR-TKI VERSUS DOUBLE-PLATINUM ALONE ON NSLCLC PATIENTS WITH DISEASE PROGRESSION AND EGFR-TKI TREATMENT ]]>
<![CDATA[Laksmi Wulandari]]>;
<![CDATA[Edward Pandu Wiriansya]]>
<![CDATA[ Folia Medica Indonesiana Vol. 53 No. 4 (2017): December 2017 ]]>
Publisher : <![CDATA[Faculty of Medicine, Universitas Airlangga ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (157.199 KB)
|
DOI: 10.20473/fmi.v53i4.7161
<![CDATA[EGFR-TKI is the first-line therapy for EGFR-mutant patients. Nevertheless, patients will have disease progression (median PFS 10 – 12 months) due to resistance. The treatment options are still limited in developing countries for such cases, thus double-platinum chemotherapy is the next option. Although IMPRESS study reported no difference in terms of PFS and OS between double-platinum alone and double-platinum plus EGFR-TKI, several local studies reported benefit of continuing EGFR-TKI in combination with double-platinum chemotherapy (treatment beyond progression). This study aimed to compare chemotherapy effects of double-platinum plus EGFR-TKI versus double-platinum alone on patients with NSCLC progression after EGFR-TKI treatment. This was an analytical descriptive study using prospective cohort design, involving 30 patients with disease progression following EGFR-TKI treatment that met inclusion criteria in Dr. Soetomo Hospital. Subjects were divided into two groups: arm A (double-platinum plus EGFR-TKI) and arm B (double-platinum alone). Subjects were observed until 4 cycles of double-platinum chemotherapy. Subjective response (body weight and EQ5D questionnaire) was analyzed, chest CT scans were evaluated using RECIST criteria, and adverse effects were monitored. This study was conducted in accordance with GCP principles and has received ethics certificate from Dr. Soetomo Hospital ethics committee (No. 08/Panke.KKE/I/2017). The results showed that subject characteristics between two arms were insignificantly different (p=0.05). The most common EGFR mutation was exon 21 (50% on arm A and 60% on arm B). Chi square was tested on subjective response parameter (EQ5D (p=0.483)). T2 free sample was tested on semi-subjective parameter (body weight (p=1.00)). Comparison test on both groups after cycle 2 and 4 showed p value=0.05. Statistical test on adverse effect between both groups showed p value=0.526. As a conclusion, there was no significant difference between double-platinum and double-platinum plus EGFR-TKI on patients who had disease progression following EGFR-TKI treatment.]]>
<![CDATA[Case report: Management of Progressive Lung Cancer Patients after First-Line EGFR Tyrosine Kinase Inhibitor Therapy ]]>
<![CDATA[Sahrun Sahrun]]>;
<![CDATA[Laksmi Wulandari]]>
<![CDATA[ Folia Medica Indonesiana Vol. 55 No. 3 (2019): September ]]>
Publisher : <![CDATA[Faculty of Medicine, Universitas Airlangga ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (244.71 KB)
|
DOI: 10.20473/fmi.v55i3.15509
<![CDATA[Various tyrosine kinase inhibitor (TKI) drugs have been widely used as therapy for cancer that has EGFR mutations, or abnormal EGFR activation. However, patients who have a mutation in the gene that activates EGFR only benefit from EGFR-TKI therapy for less than one year, because after that resistance occurs. In the management of patients according to NCCN 2017, patients who experience progress after receiving TKI as the first-line therapy must undergo an examination to identify the presence of T790M mutation. If the T790M mutation is positive, the choice of therapy that needs to be provided is the third generation (Osimertinib). Many recent studies have proved the significance of the effectiveness and response of Osimertinib therapy in lung cancer with EGFR T790M mutation. We reported the management of a pulmonary adenocarcinoma patient with positive EGFR mutation who had received first-line EGFR TKI who had progressive disease and T790M mutation in Dr. Seotomo Hospital. The patient finally received Osimertinib through an Early Access Program with a therapeutic response that improved significantly.]]>
<![CDATA[Mediastinal Non-Hodgkin's Lymphoma Metastatic to Right Atrium Mimicking Right Atrial Myxoma ]]>
<![CDATA[Gemilang Khusnurrokhman]]>;
<![CDATA[Laksmi Wulandari]]>
<![CDATA[ Folia Medica Indonesiana Vol. 57 No. 4 (2021): December ]]>
Publisher : <![CDATA[Universitas Airlangga ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (1089.158 KB)
|
DOI: 10.20473/fmi.v57i4.21031
<![CDATA[Highlight:A 32-year-old male patient suffered mediastinal non-hodgkin's lymphoma metastatic to the right atrium which mimicked right atrial myxoma.The patient died of suspected mediastinal NHL thromboembolism that spread in the right atrium. Abstract:In this case report, the anatomical pathology results in the form of B cell type LNH, but at the age of 32 years and the risk factor in this patient was a former active smoker. In the anatomical pathology results, the results of the B-High Grade Cell Type LNH were also obtained. B-cell type non-hodgkin’s lymphoma can be mutated in the MYC gene (v-myc avian myceloctomatosis viral oncogene homolog) and the BCL-2 and BCL-6 (B-cell lymphoma) genes. If this morphology is found, then the patient's prognosis is poor. Most of these patients were males and the incidence was in the mediastinal area. Mediastinal NHL could develop and enlarge to involve the heart and pericardium. The spread could occur directly and lymphogens. These metastatic tumors were often misdiagnosed with atrial myxoma. In this case report, exploration of the right atrium and open mediastinal biopsy was performed. An open biopsy of the mediastinum revealed a mediastinal mass that enlarged to enter the right atrium. Atrial myxoma was not found. Primary lymphoma growth could also occur in the heart. This condition was called primary cardiac lymphoid (PCL). This case was very rare and was often considered an atrial myxoma. The patient died 10 days after discharge from the hospital. While the patient was eating, the patient had a seizure and the patient was immediately taken to the emergency department of Dr. Soetomo General Academic Hospital, Surabaya, and entered the ER (Resuscitation) ER room, but the patient died after being assisted for approximately two hours. Most likely the cause of the patient's death was a thromboembolic tumor in the right atrium that was released, so that it entered the bloodstream of the brain, causing the patient to have seizures. It was suspected that the cause of the patient's death was the presence of a tumor thrombus that separated into an embolism from the right atrium due to the large size of the tumor. Patients suffering from high rate NHL had a greater percentage of suffering from tumor thromboembolism as many as 10.6% compared to the Low type and Hodgkins lymphoma (LH) (5.8% and 7.25%).]]>
<![CDATA[A 28-Year-Old Man With Mediastinal Seminoma Treated With BEP ]]>
<![CDATA[Agustinus Rizki]]>;
<![CDATA[Laksmi Wulandari]]>
<![CDATA[ Folia Medica Indonesiana Vol. 57 No. 4 (2021): December ]]>
Publisher : <![CDATA[Universitas Airlangga ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (669.165 KB)
|
DOI: 10.20473/fmi.v57i4.21037
<![CDATA[Highlight:A 28-year-old male suffered chylothorax and mediastinal seminoma.The patient received bleomycin, etoposide and cisplatin chemotherapy for the management of mediastinal seminomas but he died beforeundergoing 5th cycle chemotherapy. Abstract:Seminoma is a type of germ cell tumor. In this case presentation, a rare primary germ cell tumor was reported in the form of mediastinal seminoma. A 28-year-old man with symptoms of shortness of breath, chest pain, swelling in the right upper extremity, enlarged lymph nodes in the colli region. Thoracic physical examination revealed signs of pleural fluid in the right hemithorax. After obtaining the results of radiological and pathological investigations, a mediastinal mass was obtained, then BEP chemotherapy was given. After 3 cycles of chemotherapy, a partial response was obtained. Patients with mediastinal seminoma treated with BEP base chemotherapy gave a partial response.]]>
